Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 419853, 11 pages
http://dx.doi.org/10.1155/2014/419853
Research Article

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies

1Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, F46, Huddinge University Hospital, 141 86 Stockholm, Sweden
2Division of Cognitive Neurophysiology and Osher Center for Integrative Medicine, Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
3Stress Research Center, Stockholm University, 106 91 Stockholm, Sweden
4Department of Chest Diseases, Eskisehir Osmangazi University Medical Faculty, 260 40 Eskisehir, Turkey

Received 9 May 2014; Accepted 30 June 2014; Published 24 July 2014

Academic Editor: Dragana Nikitovic

Copyright © 2014 Filip Mundt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. The distinction between malignant and benign pleural effusions is a diagnostic challenge today and measuring soluble biomarkers could add to the diagnostic accuracy. Syndecan-1 is a proteoglycan involved in various cellular functions and is cleaved from the cell surface in a regulated manner. The shed fragment, which can be recovered in effusion supernatant and in serum, retains its binding capacities, but often with different functions and signalling properties than the cell-bound form. Aim. This study aimed to investigate the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera from patients with pleural malignancies. Study Design. Using two cohorts of patients, we assessed the diagnostic and prognostic value of soluble syndecan-1 in pleural effusions and sera, using enzyme-linked immunosorbent assays. Results. In pleural effusions, syndecan-1 distinguished malignant and benign diseases, with an odds ratio of 8.59 (95% CI 3.67 to 20.09). Furthermore, syndecan-1 in pleural effusions predicted a survival difference for patients with pleural metastatic disease and malignant mesothelioma of 11.2 and 9.2 months, respectively. However, no such effects were seen when syndecan-1 was measured in serum. Conclusion. Soluble syndecan-1 is a promising candidate biomarker for the cytopathological diagnosis and prognostication of malignant pleural effusions.